Ruxolitinib phosphate
- CAS NO.:1092939-17-7
- Empirical Formula: C17H21N6O4P
- Molecular Weight: 404.37
- MDL number: MFCD18452860
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-11-18 21:14:07
What is Ruxolitinib phosphate?
The Uses of Ruxolitinib phosphate
The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.
What are the applications of Application
Ruxolitinib Phosphate is a JAK1/JAK2 inhibitor
Definition
ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent al thrombocythemia myelofibrosis.
Clinical Use
Ruxolitinib phosphate is a potent, selective, ATP competitive inhibitor of tyrosine-protein kinases JAK1 and JAK2 which acts by attenuating cytokine signaling and promotes apoptosis. Ruxolitinib was discovered and developed by Incyte, is marketed under the brand name Jakafi,and is approved for the treatment of patients with myelofibrosis (MF), including primary MF, post-polycythemia vera MP, and post-essential thrombocythemia MF. Ruxolitinib is also undergoing clinical evaluation against a wide variety of cancer indications including metastatic prostate cancer, pancreatic cancer, multiple myeloma, leukemia, non-Hodgkin lymphoma, and breast cancer. Additionally, ruxolitinib is being evaluated for the treatment of psoriasis and thrombocytopenia.
Synthesis
Ruxolitinib contains
one chiral center, and three general strategies for its preparation
have been reported.165¨C167 These include a racemic synthesis
followed by chiral separation or resolution, introduction of the side
chain via an aza-Michael addition of the pyrazole fragment to 3-
cyclopentylpropiolonitrile and asymmetric hydrogenation of the
resulting alkene, and through introduction of the side chain via
an organocatalytic, asymmetric aza-Michael addition. The route
described herein utilizes the first strategy as this appears
to be the largest scale reported.
The synthesis was initiated by SEM protection of commercially
available chloropyrrolopyrimidine 201 to provide the protected
chloropyrrolopyrimidine 202 in 89% yield. Suzuki coupling of 202
with the pyrazole pinacolatoboronate 203 gave pyrazole 204 in
64% yield. aza-Michael reaction of pyrazole 204 with 3-cyclopentylacrylonitrile
205 was accomplished in the presence of DBU to furnish
SEM-protected ruxolitinib 206 in 98% yield as the racemate.
The desired enantiomer 207 was isolated via chiral column separation
in 93.5% yield and 99.4% ee, on 100 kg scale. Removal of the
SEM group was accomplished through a two step process via treatment
with lithium tetrafluoroborate and aqueous ammonium
hydroxide, ultimately giving rise to ruxolitinib 208 in 84% yield.
The phosphate salt was then prepared by treatment with phosphoric
acid. Crystallization from MeOH/i-PrOH/n-heptane gave ruxolitinib
phosphate (XX) in good overall yield in 99.8% ee. Pyrazole
pinacolatoboronate 203 was prepared from pyrazole 209 via iodination
with N-iodosuccinimide followed by reaction with trimethyl
silyl chloride to give protected iodopyrazaole 210 in high yield.
Reaction of 210 with i-PrMgCl to form the corresponding Grignard
reagent followed by reaction with isopropylpinacolborane 211
provided Suzuki boronate synthon 203 in 55% yield.
storage
Store at -20°C
Properties of Ruxolitinib phosphate
Melting point: | 186-190°C |
storage temp. | Refrigerator |
solubility | DMSO (Slightly), Methanol (Slightly) |
form | Solid |
color | White to Off-White |
Safety information for Ruxolitinib phosphate
Signal word | Danger |
Pictogram(s) |
Skull and Crossbones Acute Toxicity GHS06 Health Hazard GHS08 |
GHS Hazard Statements |
H301:Acute toxicity,oral H361:Reproductive toxicity H373:Specific target organ toxicity, repeated exposure |
Precautionary Statement Codes |
P260:Do not breathe dust/fume/gas/mist/vapours/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P308+P313:IF exposed or concerned: Get medical advice/attention. |
Computed Descriptors for Ruxolitinib phosphate
Abamectin manufacturer
Aspen Biopharma Labs Pvt Ltd
New Products
4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium THOMAIND PAPER PH 2.0 TO 4.5 1 BOX BUFFER CAPSULE PH 9.2 - 10 CAP SODIUM CHLORIDE 0.1N CVS ALLOXAN MONOHYDRATE 98% PLATINUM 0.5% ON 3 MM ALUMINA PELLETS (TYPE 73) LITHIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
1092939-17-7 Ruxolitinib Phosphate 98%View Details
1092939-17-7 -
Ruxolitinib phosphate 98%View Details
1092939-17-7 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%View Details
1805639-70-6 -
1784294-80-9 98%View Details
1784294-80-9 -
Lithium ClavulanateView Details
61177-44-4